Feb 02,2023

Blood Test Offers Hope For Lung Cancer Patients

A new blood test will help US doctors determine the best treatment options for lung cancer patients who can’t be operated on. The test, developed by Israeli company OncoHost, scans approximately 7,000 proteins in a patient’s blood plasma to deliver a report that predicts their clinical benefit from immunotherapy-based treatment.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Feb 02,2023

Sleep Number Honored with American Cancer Society’s 2022 Corporate Partner of the Year Award

In advance of World Cancer Day on February 4, Sleep Number Corporation (Nasdaq: SNBR) today announces it is the proud recipient of the American Cancer Society’s (ACS) 2022 Corporate Partner of the Year Award. Over the next five years, ACS will leverage Sleep Number’s proprietary sleep data and sleep expertise in its research to identify the impact of quality sleep on cancer prevention and recovery.

#rwd

View Analyst & Ambassador Comments
Go to original news
Feb 02,2023

Philips joins European Federation for Cancer Images (EUCAIM) to advance precision medicine for Europe’s cancer patients

Philips is an active participant in the new European Union (EU) European Federation for Cancer Images consortium (EUCAIM) – a cornerstone project in the European Cancer Imaging Initiative that was launched by the European Commission in the run-up to World Cancer Day 2023. Addressing the need for researchers and innovators to access real-world oncology data at the scale and quality needed to develop new solutions to help detect, diagnose and treat cancer, notably those based on artificial intelligence (AI), the European Cancer Imaging Initiative will work towards creating a digital infrastructure that links up resources and databases of cancer imaging data across the EU, while ensuring adherence to high standards of ethics, trust, security, and data protection.

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 03,2023

SCOPE Summit will bring together leaders and innovators in clinical research

Massive Bio CEO Selin Kurnaz will attend the 14th SCOPE Summit, which focuses on advances and innovations in all aspects of clinical trials, and will be held in Orlando, Florida, on February 6-9. SCOPE Summit, one of the most important annual gatherings in the field of clinical research, will take place on February 6-9, 2023, at Rosen Shingle Creek, a hotel and resort in Orlando, Florida. Celebrating its 14th anniversary, the summit will feature conferences, plenary keynote sessions, and interactive discussions focused on advances and innovative solutions in all aspects of clinical trial planning, management and operations.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 07,2022

Global Digital Health 100 – The Medical Futurist’s Top Choices in 2022

Digital health is booming, with dozens, hundreds of startups and scale-ups entering the realm each year. While their spectacular promises are loud, failure is silent – unless it happens to one of the tech giants – many of the former prodigies quietly go out of business after a few years. To help navigate this rapidly changing field, here is a Top 100 list, introducing new companies that are worthy of attention, including Sidekick Health who closed a partnership with Eli Lilly in the oncology segment, as well as Google's DeepMind AI which detects breast cancer and many more.

#ai/software

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 09,2022

Careology joins Aviva’s cancer support services

Careology will join the cancer support services offered to Aviva’s private medical insurance members (on large corporate healthcare schemes). Access to Careology will be provided to members with a cancer diagnosis, to help patients manage their treatment more effectively. Careology is the first intelligent technology that empowers people living and dealing with cancer to feel in control of their care. We do this by helping patients to easily navigate key elements of treatment in a digital-first way, while seamlessly connecting to clinicians, caregivers and family.

COLLABORATION PARTNERSHIP

#insurance

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Nov 09,2022

Tempus Announces Six Abstracts Accepted for Presentation at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Tempus, a leader in artificial intelligence and precision medicine, today announced that six abstracts were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, which convenes in Boston, Massachusetts, from November 8-12, 2022. Tempus continues to be a leader in advancing immunotherapy research, demonstrated in the research presented this year, which includes an oral presentation and five poster presentations.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 10,2022

How Technology Can Help Match Cancer Patients with Cancer Trials

As science propels cancer treatments forward, clinical trials are increasingly designed around very small genetically defined subsets of cancers which, at certain stages, makes finding eligible patients difficult. Even with the recent Centers for Disease Control and Prevention (CDC) infusion of $215 million as part of a five-year, $1.1 billion grant to fund the first year of three national programs to improve cancer prevention, detection, diagnosis, and control, investment is not being directed to fix the most fundamental problems in cancer research.

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 11,2022

Global Artificial Intelligence (AI) in Medical Diagnostics Market Report 2022: Evolving Industrial IoT and Automation Technologies Boost Sector

The global AI in medical diagnostics market is projected to reach USD 5.5 Billion by 2027 from USD 1.0 Billion in 2022, at a CAGR of 39.9% during the forecast period. The adoption of AI in medical diagnostics is growing at a fast pace owing to factors such as rise in various government initiatives to drive the uptake of AI-based technologies, AI solutions being more use by radiologists to reduce workload, the influx of big data, fundings made available for AI-based startups, and the growing number of cross-industry partnerships & collaborations.

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 11,2022

OncoHost to present proteomics-based biomarker model for clinical benefit to immunotherapy in NSCLC patients at SITC 2022

OncoHost has developed a novel predictive model for clinical benefit of immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients. The model is based on proteomic profiling of pre-treatment blood samples, combined with machine learning analysis that accurately predicts clinical benefit probability at twelve months, outperforming the predictive capabilities of the existing PD-L1 biomarker. The predictive model was developed on a cohort of 339 ICI-treated NSCLC patients taking part in OncoHost's ongoing, multicenter PROPHETIC clinical trial.

CLINICAL STUDY

#platform

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY